Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?

The efficacy of mebeverine 200 mg compared to mebeverine 135 mg indicated RRs of 1.12 ( P = 0.168) for clinical or global improvement and 1.08 ( P = 0.463) for relief of abdominal pain.[ 9 ] Therefore, although mebeverine was shown to be well-tolerated, its efficacy in global improvement of IBS did not reach statistical significance.

also in 111,027 other papers